DPI-386 clinical trials
A product of Scopolamine; its studies count on that page too.
How each study uses DPI-386 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DPI-386 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Dec 1979 · TRANSDERM SCOP · NDA 017874 (FDA, Drugs@FDA; as Scopolamine)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Repurposed Therapeutics, Inc. (6)
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Scopolamine
Studies
Open first, then newest update. How each study uses DPI-386 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformanceRecruitingPhase 2Repurposed Therapeutics, Inc.NCT05886660Written as DPI-386 Nasal Gel
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformanceRecruitingPhase 2Repurposed Therapeutics, Inc.NCT05852730Written as DPI-386 Nasal Gel
- Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionCompletedPhase 3Repurposed Therapeutics, Inc.NCT05548270Written as DPI-386 Nasal Gel
- Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionCompletedPhase 3Repurposed Therapeutics, Inc.NCT04947423Written as DPI-386 Nasal Gel
- DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion SicknessTerminatedPhase 2/3Repurposed Therapeutics, Inc.NCT04219982Written as DPI-386 Nasal Gel
- Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion SicknessCompletedPhase 3Repurposed Therapeutics, Inc.NCT04184115Written as DPI-386 Nasal Gel